WORX

SCWorx is a $5.3M sub-dollar micro-cap whose own 10-K states that its conditions 'raise substantial doubt about our ability to continue as a going concern.' That is the whole thesis: this is not a valuation debate, it is a survival question. Revenue has fallen every year from $4.63M (FY2021) to $2.88M (FY2025), down another 3.7% last year, and management explicitly warns the decline 'may continue if we are unable to develop and market new products.' A healthcare-data SaaS that cannot grow off a $3M base is a structurally weak franchise, and five straight years of net losses (accumulated deficit -$35.4M) confirm the model has never worked at scale.

The FY2025 numbers are worse than the modest operating figures suggest. Operating loss narrowed to -$959K, but net loss ballooned 291% to -$4.44M and diluted EPS was -$0.61 — meaning ~$3.5M of non-operating charges (likely financing/derivative costs tied to the Notes) hit the bottom line. Operating cash flow was -$1.54M against just $1.64M of cash; that is roughly one year of runway. The balance sheet looks superficially clean (liabilities/equity 0.10x, equity $7.15M), but that equity was manufactured by diluting shareholders into oblivion — shares outstanding rose 659.8% year-over-year. Existing holders were nearly wiped out to keep the lights on, and the filing signals more of the same.